Results 261 to 270 of about 124,717 (304)
Some of the next articles are maybe not open access.
Beyond immune checkpoint blockade: emerging immunological strategies
Nature Reviews Drug Discovery, 2021The success of checkpoint inhibitors has accelerated the clinical implementation of a vast mosaic of single agents and combination immunotherapies. However, the lack of clinical translation for a number of immunotherapies as monotherapies or in combination with checkpoint inhibitors has clarified that new strategies must be employed to advance the ...
Shawn P. Kubli +4 more
openaire +4 more sources
Hematology/Oncology Clinics of North America, 2014
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo +2 more
openaire +2 more sources
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo +2 more
openaire +2 more sources
Immune Checkpoint Blockade in Malignant Mesothelioma
Seminars in Oncology, 2015Malignant mesothelioma (MM) is a highly aggressive malignancy with a very dismal prognosis. Current treatment for unresectable MM is largely unsatisfactory; therefore, new therapeutic approaches are eagerly awaited. A better understanding of the complex mechanisms of immune escape operated by neoplastic cells and the ability to unleash an efficient ...
Calabro' L, Maio M.
openaire +3 more sources
Combined Immune Checkpoint Blockade
Seminars in Oncology, 2015There are very few tumor types for which chemotherapy regimens are regularly curative; notable exceptions include testicular cancer and Hodgkin's lymphoma. In both cases combination chemotherapy approaches are required. Thus, it would seem only logical that combination immunotherapy approaches will be required to induce long-term remissions in the ...
openaire +2 more sources
Presurgical immune checkpoint blockade
Science, 2020Cancer Immunotherapy Checkpoint blockade immunotherapy using antibodies that inhibit the programmed cell death 1 (PD-1) or cytotoxic T lymphocyte–associated protein 4 (CTLA-4) pathways has resulted in unprecedented clinical outcomes for certain cancers such as melanoma. Topalian et al.
openaire +1 more source
Delivery Strategies for Immune Checkpoint Blockade
Advanced Healthcare Materials, 2018AbstractImmune checkpoint blockade, which blocks the regulatory pathways that express on immune cells to improve antitumor immunological responses, is becoming one of the most promising approaches for antitumor therapy. This therapy has achieved important clinical advancement and provided a new opportunity against a variety of cancers.
Qian Chen +4 more
openaire +2 more sources
Fertility post immune checkpoint blockade.
Journal of Clinical Oncology, 202312014 Background: Immune checkpoint blockade (ICB) is radically altering the treatment paradigm for a wide range of malignancies. Consequently, the proportion of ICB exposed pts will expand and the impact of ICB on fertility is of increasing importance. We sought to evaluate fertility outcomes post ICB exposure at our institution.
Martinique Ogle +7 more
openaire +1 more source
Combining chemotherapy and immune checkpoint blockade
Current Opinion in Urology, 2016Immune checkpoint blockade results in durable responses in a subset of patients with advanced urologic tumors. However, the majority of patients do not respond to single agent therapy raising the hypothesis that combination regimens may extend the benefits of immune checkpoint blockade to an even broader patient population.
Ana, Collazo-Lorduy, Matthew D, Galsky
openaire +2 more sources
Immune Checkpoint Blockade and Skin Toxicity Pathogenesis
Journal of Investigative Dermatology, 2022Immune checkpoint blockade has revolutionized the treatment of multiple tumor types, including melanoma and nonmelanoma skin cancers. The use of immune checkpoint blockade is curtailed by tissue toxicities termed immune-related adverse events (irAEs), which occur most quickly and most often in the skin.
Barbara Ma, Niroshana Anandasabapathy
openaire +2 more sources